Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 May 2018

The National Research Foundation (NRF) ratings are considered the benchmark for research excellence. This year the University of the Free State (UFS) has 17 newly NRF-rated researchers. This brings the total number of NRF-rated researchers at UFS to 160.
 
NRF ratings are allocated based on a researcher’s recent research outputs and impact as perceived by national and international peer reviewers. The rating system encourages researchers to publish high-quality research papers in journals of high impact and to publish books through reputed academic publishers. The NRF rating system is a valuable tool for benchmarking the quality of our researchers against the best in the world.

Research at the heart of the UFS
Prof Francis Petersen, Rector and Vice-Chancellor, has indicated that the UFS provides significant support to researchers to apply for new NRF ratings or to re-apply for rating. These initiatives include the mock NRF rating panels managed by the Prestige Scholars Programme (PSP), evaluation of individual research outputs and recommendations on timely applying for rating, and improvements on rating applications by a panel consisting of internal and external members. These initiatives are bearing fruit by increasing the number of rated researchers who will transform the research profile and increase the diversity of UFS researchers.
Cultivating the best researchers.

According to Eleanor van der Westhuizen, from Research Development: “The rating of individuals is based primarily on the quality and impact of their research outputs over the past eight years, taking into consideration the evaluation made by local and international peers. It identifies researchers who count among the leaders in their fields of expertise and gives recognition to those who have a sustained production of high-quality research outputs. Several South African universities use the outcomes of the NRF evaluation and rating process to position themselves as research-intensive institutions, while others such as the UFS provide incentives for their staff members to acquire and maintain a rating.”

Cream of the crop
The UFS has also upped the ante with regard to its total number of NRF-rated researchers during the latest rating and evaluation, with an increase from 149 to 160 rated researchers in 2018.
 
Prof Heidi Hudson, Dean of Humanities, received an NRF B-rating, which brings the total of B-rated researchers to six. Other B-rated researchers incude Prof Johann Meyer (Mathematics), Prof Fanie Snyman and Prof Francois Tolmie (Theology), Prof Felicity Burt (Medical Microbiology) and Prof Andre Roodt (Chemistry). A total number of 10 new C-ratings and six new Y-ratings were achieved during the 2018 evaluation process.

“NRF-rating is indicative of the university’s drive to enhance its research profile nationally and internationally. Congratulations to all the scientists and scholars who received a rating in 2017. I am thankful to our academics for their commitment to the rating process,” said Prof Corli Witthuhn, Vice-Rector: Research at the UFS.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept